Renalytix is a diagnostics company focused entirely on a single product: kidneyintelX.dkd, the first FDA-authorized prognostic test for chronic kidney disease (CKD) in patients with type 2 diabetes. The test combines three blood-based biomarkers with patient data from electronic health records, analyzed by a machine learning algorithm, to predict the risk of kidney function decline over a five-year horizon. Results are delivered as a simple risk score directly to the ordering physician through their EHR system. Renalytix processes blood samples in its CLIA-certified lab in New York City and bills per test at $950, set by the Medicare Clinical Lab Fee Schedule. The company sells directly to primary care physicians through a field sales force, concentrated in high-diabetes-density regions where insurance coverage is broadest. Revenue depends on test volume and collection rates, with some revenue deferred until payment history is established with new payers. Key IP is licensed from the Joslin Diabetes Center and the Icahn School of Medicine at Mount Sinai, with royalties of 4-5% and 5% of net sales respectively. Renalytix's growth strategy centers on expanding its direct sales force, deepening EHR integration with large health systems to drive routine ordering, and broadening commercial payer contracts. The company is also exploring international licensing partnerships and potential expansion of the KidneyIntelX platform to additional CKD applications.